[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606282":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":56,"collaborators":24,"id":59,"slug":24,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":24,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Houston","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fitzpatrick skin tone I-IV","EXPERIMENTAL","Individuals with skin tones I-IV on the Fitzpatrick scale will receive low-level light therapy",[13],"Device: Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).",{"label":15,"type":10,"description":16,"interventionNames":17},"Fitzpatrick skin tone V-VI","Individuals with skin tones V-Vi on the Fitzpatrick scale will receive low-level light therapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).","A mask with Light Emitting Diodes wavelength 633nm will be placed over closed eyes for 15 minutes.",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Eric Ritchey, OD, PhD","CONTACT","713-743-1933","erritche@central.uh.edu",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"Rachel Redfern, OD, PhD","713-743-1943","rredfern@uh.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The University of Houston College of Optometry","RECRUITING","Houston","Texas","77204","United States",{"type":44,"coordinates":45},"Point",[46,47],-95.36327,29.76328,{"lat":47,"lon":46},[50,52,53,55],{"name":27,"role":28,"phone":51,"phoneExt":24,"email":30},"7137431933",{"name":24,"role":28,"phone":24,"phoneExt":24,"email":30},{"name":27,"role":54,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"name":32,"role":54,"phone":24,"phoneExt":24,"email":24},{"type":54,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Eric R. Ritchey","Associate Professor","100606282",false,"NCT07173530","Low Level Light Therapy & Skin Pigmentation","Inclusion Criteria:\n\n* Ability to read and understand the study informed consent in English\n* Age 18 years or older at enrollment\n* Individuals with MGD based on one or more of the following clinical signs\u002Fsymptoms, e.g., meibum quality score of 1-3 (Bron et al.), meibography score of 1, 2, or 3 on the Pult Meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an Ocular Surface Disease Index (OSDI) score greater than 12 points.\n\nExclusion Criteria:\n\n* Active anterior segment pathology (e.g., bacterial conjunctivitis, microbial keratitis)\n* History of systemic disease associated with aqueous-deficient dry eye disease (e.g., Sjogren's syndrome)\n* History of corneal surgery, refractive surgery, or eyelid surgery within 6 months\n* History of corneal ectasia (e.g. keratoconus, Pellucid marginal degeneration)\n* History of ocular trauma within 6 months\n* History of LipiFlow, iLux, Meiboflow, IPL or LLLT within the last 12 months\n* Habitual use of photosensitizing medications within the last 30 days\n* Pregnant and\u002For lactating females, by self-report\n* Pigmented lesions, tattoos, or skin cancer in the periocular region\n* Unwilling to have eyes photographed or video recorded","ALL","18 Years",{"count":67,"type":68},40,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this clinical trial is to determine if there is a difference in eyelid temperature after low-level light therapy (LLLT) in individuals with different amounts of skin pigmentation and dry eye\u002Fmeibomian gland disease. Participants will have 3 fifteen minute in office LLLT therapy sessions over a period of approximately 7 to 14 days.",[74,75],"Dry Eye","Meibomian Gland Dysfunction (Disorder)",[74,77,78,79],"Meibomian Gland","LLLT","Low-level light therapy","2025-09-08",{"date":82,"type":83},"2025-09-15","ACTUAL",{"date":85,"type":83},"2025-06-11",{"date":87,"type":68},"2026-08",{"name":5,"class":6},1]